Use of ADHD drugs in the Nordic countries: a population-based comparison study
Article first published online: 23 SEP 2010
© 2010 John Wiley & Sons A/S
Acta Psychiatrica Scandinavica
Volume 123, Issue 5, pages 360–367, May 2011
How to Cite
Zoëga, H., Furu, K., Halldórsson, M., Thomsen, P. H., Sourander, A. and Martikainen, J. E. (2011), Use of ADHD drugs in the Nordic countries: a population-based comparison study. Acta Psychiatrica Scandinavica, 123: 360–367. doi: 10.1111/j.1600-0447.2010.01607.x
- Issue published online: 14 APR 2011
- Article first published online: 23 SEP 2010
- Accepted for publication August 27, 2010
- drug utilisation;
- central nervous system stimulants;
- attention-deficit/hyperactivity disorder
Zoëga H, Furu K, Halldórsson M, Thomsen PH, Sourander A, Martikainen JE. Use of ADHD drugs in the Nordic countries: a population-based comparison study.
Objective: To compare national use of attention-deficit/hyperactivity disorder (ADHD) drugs between five Nordic countries.
Method: A population-based drug utilisation study based on nationwide prescription databases, covering in total 24 919 145 individuals in 2007. ADHD drugs defined according to the World Health Organization Anatomic Therapeutic Chemical classification system as centrally acting sympathomimetics (N06BA).
Results: The 2007 prevalence of ADHD drug use among the total Nordic population was 2.76 per 1000 inhabitants, varying from 1.23 per 1000 in Finland to 12.46 per 1000 in Iceland. Adjusting for age, Icelanders were nearly five times more likely than Swedes to have used ADHD drugs (Prev.Ratio = 4.53, 95% CI: 4.38–4.69). Prevalence among boys (age 7–15) was fourfold the prevalence among girls (Prev.Ratio = 4.28, 95% CI: 3.70–4.96). The gender ratio was diminished among adults (age 21 +) (Prev.Ratio = 1.24, CI: 1.21–1.27).
Conclusion: A considerable national variation in use of ADHD drugs exists between the Nordic countries.